Oxime-induced reactivation of acetylcholinesterase inhibited by organophosphinates
β Scribed by D. W. Hanke; M. S. Beckett; M. A. Overton; C. K. Burdick; C. N. Lieske
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 499 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0260-437X
No coin nor oath required. For personal study only.
β¦ Synopsis
Defense. Aherdeen Proving Ground. MD 21010-5425. USA K e y word5 organophosphinate, orgdnophosphonatc. harin, oxiiiieq ,icetylcholinesterasc. rexti\dtioii. pretrc'itment
The comparative potency of oximes for reactivation of inhibited eel acetylcholinesterase (AChE) in vitro is dependent on the organophosphinate inhibitor. Some of the data, dealing with a reference organophosphonate, support the conclusion of other investigators that the oxime potency order is also dependent on the inhibiting phosphonate. This work was done to identify more clearly the nature of phosphinylated AChE with regard to oxime reactivation potency and the potential of phosphinates as pretreatment drugs to protect AChE against organophosphonate poisoning. We have determined the reactivation potency of four oximes-2-PAM, HI-6, TMB-4 and toxogonin-against four phosphinates-4-nitrophenyl methyl(pheny1)phosphinate (PMP). 4nitrophenyl chloromethyl(pheny1)phosphinate (CPMP), 4-nitrophenyl trifluoromethyl(phenyI) phosphinate and 4-nitrophenyl bis(2-thieny1)phosphinate. For comparison, the phosphonate sarin (GB, isopropyl methylphosphonofluoridate) was included. Incubation of the inhibited enzyme (I-AChE) at 25Β°C was with 0.30 p M oxime for PMP, 3.0 p M oxime for sarin and CPMP and 100 p M oxime for the two remaining phosphinates. AChE activity was assayed spectrophotometrically for 3.0 min at 272.5 nm at 25Β°C in 0.10 M MOPS buffer (pH 7.60) using phenyl acetate as substrate. When sarin was the inhibitor (0% spontaneous recovery after a 2-h incubation), the order of oxime reactivation was 2-PAM (46%) 3 toxogonin (33%) = TMB-4 (31%) > HI-6 (9%) after 2-h incubations. For PMP (12% spontaneous recovery after a 2-h incubation) the oxime order was toxogonin (67%) > TMB-4 (53%) > 2-PAM (40%) after 2-h incubations. For CPMP (8% spontaneous recovery after a 30-min incubation) the order was toxogonin (65%) = TMB-4 (59%) = HI-6 (57%) > 2-PAM (12%) after 30-min incubations. For the trifluorophosphinate the order was toxogonin (18%) = TMB-4 (17%) 3 HI-6 (12%) 2 2-PAM (3%) after 5-min incubations. For the bis-thienylphosphinate the order was HI-6 (38%) > 2-PAM (20%) > TMB-4 (0.4%) > toxogonin (0%) after 5-min incubations.
Despite some uncertainty in the oxime orders, these results support the conclusion that oxime potency is dependent on the organophosphinate used as the AChE inhibitor. The results also broaden the database that underpins the generally accepted conclusion, that for a given oxime its reactivation potency is dependent on the organophosphorous compound wed to inhibit AChE.
π SIMILAR VOLUMES
Oximes are enzyme reactivators used in treating poisoning with organophosphorus cholinesterase (AChE) inhibitors. The oxime dose which can be safely administered is limited by the intrinsic toxicity of the substances such as their own AChE-inhibiting tendency. Clinical experience with the available
In our study, we have tested six acetylcholinesterase (AChE) reactivators (pralidoxime, obidoxime, HI-6, trimedoxime, BI-6 and HlΓΆ-7) for reactivation of sarin-and cyclosarin-inhibited AChE using an in vitro reactivation test. We have used rat brain homogenate as the suitable source of enzyme. All o